Cencora (COR) Stock Forecast & Price Target

$283.12 -0.65 (-0.23%)

As of 05/9/2025 03:53 PM Eastern

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
2

Buy
8

Based on 10 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, and 8 have given a buy rating for COR.

Consensus Price Target

$301.18
6.38% Upside

According to the 10 analysts' twelve-month price targets for Cencora, the average price target is $301.18. The highest price target for COR is $355.00, while the lowest price target for COR is $274.00. The average price target represents a forecasted upside of 6.38% from the current price of $283.12.

Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

COR Analyst Ratings Over Time

Type	Current Forecast 5/10/24 to 5/10/25	1 Month Ago 4/10/24 to 4/10/25	3 Months Ago 2/10/24 to 2/9/25	1 Year Ago 5/11/23 to 5/10/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	9 Buy rating(s)	7 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$301.18	$280.20	$277.90	$233.90
Forecasted Upside	6.38% Upside	0.42% Upside	12.08% Upside	4.14% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cencora Stock vs. The Competition

Type	Cencora	Medical Companies	S&P 500
Consensus Rating Score	2.80	2.81	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	6.38% Upside	4,490.76% Upside	16.98% Upside
News Sentiment Rating	Positive News See Recent COR News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
5/8/2025	Citigroup 2 of 5 stars	Michael Rollins Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$330.00 ➝ $355.00	+23.80%
5/8/2025	Robert W. Baird 2 of 5 stars	David Rodgers Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$314.00 ➝ $350.00	+15.12%
4/29/2025	UBS Group 3 of 5 stars	Kevin Caliendo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$298.00 ➝ $335.00	+16.26%
4/15/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$288.00	+1.22%
4/11/2025	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Michael Funk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$270.00 ➝ $285.00	+2.14%
3/14/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Equal Weight ➝ Equal Weight	$251.00 ➝ $274.00	+7.22%
2/6/2025	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	John Belton Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$270.00 ➝ $280.00	+12.80%
1/24/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$289.00 ➝ $301.00	+21.13%
12/4/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold ➝ Outperform	$280.00	+11.98%
11/7/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$263.00 ➝ $290.00	+18.18%
Get the Latest News and Ratings for COR and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cencora and its competitors with MarketBeat's FREE daily newsletter.
10/7/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$277.00 ➝ $275.00	+25.03%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$205.00 ➝ $215.00	+15.07%
5/26/2023	888 Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Maintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:18 PM ET.

Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, May 7, 2025. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

Here are some ways that investors could benefit from investing in Cencora, Inc.:

The current stock price is around $304, reflecting a recent increase, which may indicate positive market sentiment towards the company.
Cencora, Inc. has received multiple upgrades from analysts, with a recent rating change to "buy," suggesting strong future performance expectations.
Institutional investors hold a significant majority of the company's stock, indicating confidence from large financial entities in Cencora, Inc.'s growth potential.
The company has shown robust trading activity, with a recent volume surpassing its average, which can signal increased investor interest and liquidity.
Recent insider transactions show executives selling shares at high prices, which may reflect their confidence in the company's valuation and future prospects.

Cencora
Bear Case

Investors should be bearish about investing in Cencora, Inc. for these reasons:

The company's high price-to-earnings (P/E) ratio suggests that the stock may be overvalued compared to its earnings, which could deter value-focused investors.
Recent insider selling could raise concerns about the executives' confidence in the company's short-term performance, potentially signaling issues ahead.
Cencora, Inc. has a relatively low current ratio, indicating potential liquidity issues, which could affect its ability to meet short-term obligations.
The company's debt-to-equity ratio is quite high, suggesting that it relies heavily on debt financing, which can be risky in volatile market conditions.
Market fluctuations and economic uncertainties could impact the pharmaceutical sector, affecting Cencora, Inc.'s performance and stock price.

COR Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $301.18, with a high forecast of $355.00 and a low forecast of $274.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.
: According to analysts, Cencora's stock has a predicted upside of 6.38% based on their 12-month stock forecasts.
: Cencora has been rated by research analysts at Bank of America, Citigroup, Morgan Stanley, Robert W. Baird, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like Cencora less than other "medical" companies. The consensus rating score for Cencora is 2.80 while the average consensus rating score for "medical" companies is 2.81. Learn more on how COR compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:COR) was last updated on 5/10/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cencora (COR) Stock Forecast & Price Target